Inflammation-related biomarkers as predictors of pathological complete response in early-stage breast cancer

被引：0

作者：

Oraianthi Fiste ^{[1
]}

Evangelos Mavrothalassitis ^{[1
]}

Alexandros Kokkalis ^{[2
]}

Maximilian Anagnostakis ^{[1
]}

Georgia Gomatou ^{[1
]}

Athanasios Kontogiannis ^{[1
]}

Dimitra Karaviti ^{[1
]}

Eleftheria Karaviti ^{[1
]}

Nikolaos Konstantinos Syrigos ^{[1
]}

Athanasios Kotsakis ^{[2
]}

Elias Alexandros Kotteas ^{[1
]}

机构：

[1] Oncology Unit, Third Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens

[2] Department of Medical Oncology, University Hospital of Larissa, Larissa

来源：

Clinical and Translational Oncology | 2025年 / 27卷 / 6期

关键词：

Biomarkers; Breast cancer; Lymphocytes; Neoadjuvant therapy; Neutrophils; Pathologic complete response; Platelets;

D O I：

10.1007/s12094-024-03814-9

中图分类号：

学科分类号：

摘要：

Background: Neoadjuvant systemic therapy (NAT) represents an attractive option for improved outcomes of early-stage breast cancer (BC) patients, as it can significantly reduce tumor burden thus permitting breast-conserving resections. Equally important, the eradication of viable cancer cells post-NAT, also known as pathological complete response (pCR), has emerged as a strong prognostic biomarker, reflecting tumor’s biology and subsequent treatment responses. Yet to date, no validated markers predictive of pCR have been identified. Methods: The present retrospective study aimed to explore the value of neutrophil-tolymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as potential predictors of pCR. Results: Despite no statistically significant associations have been reported, NLR and PLR dynamics during NAT, as longitudinal inflammatory phenotypes, merit further investigation in larger cohorts. Conclusion: In the future, the integration of a comprehensive inflammatory biomarker panel into clinical practice could assist in a priori treatment selection process. © The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO) 2024.

引用

页码：2453 / 2460

页数：7

共 42 条

[1] Cancer of the Breast (Female) - Cancer Stat Facts, (2024)
[2] Oeffinger K.C., Fontham E.T.H., Etzioni R., Herzig A., Michaelson J.S., Shih Y.C.T., Et al., Breast cancer screening for women at average risk: 2015 Guideline update from the American Cancer Society, JAMA, 314, 15, pp. 1599-1614, (2015)
[3] Bleyer A., Welch H.G., Effect of three decades of screening mammography on breast-cancer incidence, N Engl J Med, 367, 21, pp. 1998-2005, (2012)
[4] Gianni L., Pienkowski T., Im Y.H., Tseng L.M., Liu M.C., Lluch A., Et al., 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial, Lancet Oncol, 17, 6, pp. 791-800, (2016)
[5] Schneeweiss A., Chia S., Hickish T., Harvey V., Eniu A., Waldron-Lynch M., Et al., Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer, Eur J Cancer, 1, 89, pp. 27-35, (2018)
[6] Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, The Lancet, 384, 9938, pp. 164-172, (2014)
[7] von Minckwitz G., Huang C.S., Mano M.S., Loibl S., Mamounas E.P., Untch M., Et al., Trastuzumab emtansine for residual invasive her2-positive breast cancer, N Engl J Med, 380, 7, pp. 617-628, (2019)
[8] Loibl S., Jassem J., Sonnenblick A., Parlier D., Winer E., Bergh J., Et al., VP6–2022: adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 84 years’ follow-up, Ann Oncol, 33, 9, pp. 986-987, (2022)
[9] Kinoshita T., Goto T., Links between inflammation and postoperative cancer recurrence, J Clin Med, 10, 2, (2021)
[10] Kim S., Takahashi H., Lin W.W., Descargues P., Grivennikov S., Kim Y., Et al., Carcinoma produced factors activate myeloid cells via TLR2 to stimulate metastasis, Nature, 457, 7225, pp. 102-106, (2009)

← 1 2 3 4 5 →